Skip to main content

Table 1 Identification of differentially expressed proteins between ASt and nASt by iTRAQ-based proteomics

From: Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study

No

Protein information

Peptide detection

Fold changea

Rec. protein name

UniprotID

Rec. symbol

MW

Peptide score

Peptide coverage

Unique peptides

ASt/nASt

ASt/NC

nASt/NC

1

Polymeric immunoglobulin receptor

P01833

PIGR

83

29.78

1.05

1

3.628

3.002

n.d.

2

Serum amyloid A protein 1

P02735

SAA1

14

409.61

54.1

6

3.201

3.023

n.d.

3

Heat shock 60 kDa protein 1

P10809

HSPD1

61

65.56

3.66

1

2.313

n.d.

n.d.

4

Orosomucoid

P02763

ORM1

24

72.88

18.91

3

1.884

1.233

n.d.

5

SCAN domain containing 3

Q6R2W3

ZNF452

152

13.59

0.38

1

1.629

1.424

n.d.

6

DEAD box polypeptide 41

Q9UJV9

DDX41

70

32.35

0.96

1

1.479

n.d.

n.d.

7

Serpin peptidase inhibitor, antityripsin member 3

P01011

SERPINA3

48

160.91

10.4

4

1.464

n.d.

n.d.

8

Serum amyloid A-4, constitutive

P35542

SAA4

15

103.51

21.54

3

1.452

n.d.

n.d.

9

Fatty acid synthase

P49327

FASN

273

30.66

0.52

1

1.417

2.308

1.675

10

Inter-alpha-trypsin inhibitor heavy chain H3

Q06033

ITIH3

100

139.48

5.84

5

1.364

n.d.

n.d.

11

Alpha-1B-glycoprotein

P04217

A1BG

54

157.16

13.74

6

1.348

n.d.

n.d.

12

Lipopolysaccharide binding protein

P18428

LBP

53

437.6

22.04

9

1.336

1.793

1.345

13

Retinol binding protein 4

P02753

RBP4

23

48.89

4.98

1

1.276

n.d.

n.d.

14

Ribosomal protein S6

P62753

RPS6

29

22.91

6.83

1

1.229

n.d.

n.d.

15

Secreted phosphoprotein 2, 24 kDa

Q13103

SPP24

24

22.13

4.27

1

1.22

1.208

n.d.

16

Fibrinogen gamma chain

P02679

FGG

52

1307.66

63.58

29

1.212

n.d.

n.d.

17

Complement factor H-related protein 1

Q03591

FHR1

38

465.78

36.97

2

1.211

n.d.

n.d.

18

Fibrinogen alpha chain

P02671

FGA

95

2078.11

46.88

40

1.207

n.d.

n.d.

19

Hemopexin

P02790

HPX

52

245.23

22.73

8

1.204

n.d.

n.d.

20

von Willebrand factor

P04275

VWF

309

343.44

4.41

11

0.816

n.d.

n.d.

21

Keratin 2

P35908

KRT2

65

288.46

11.58

6

0.814

0.723

n.d.

22

Pregnancy-zone protein

P20742

PZP

164

422.01

10.86

11

0.803

n.d.

n.d.

23

Apolipoprotein E

P02649

APOE

36

1149.96

66.25

22

0.786

n.d.

n.d.

24

Thrombospondin 1

P07996

THBS1

129

112.25

4.79

4

0.779

0.709

0.825

25

Gelsolin

P06396

GSN

86

225.78

11.64

6

0.762

n.d.

n.d.

26

Insulin-like growth factor-binding protein 3

P17936

IBP3

32

25.36

5.84

1

0.758

n.d.

n.d.

27

Extracellular matrix protein 1

Q16610

ECM1

61

365.78

22.41

9

0.736

n.d.

n.d.

28

Annexin 1

P04083

ANXA1

39

31.01

4.34

1

0.726

n.d.

n.d.

29

Hyaluronoglucosaminidase 1

Q12794

HYAL1

48

40.73

5.52

1

0.657

0.716

n.d.

30

Serpin F1

P36955

PEDF

46

33.05

2.15

1

0.586

n.d.

n.d.

31

Annexin A2 pseudogene 2

A6NMY6

ANXA2P2

39

30.15

4.72

1

0.357

n.d.

n.d.

  1. aFor a candidate protein, the fold change (ratio) of at least or more than 1.2, and at least or less than 0.80 in plasma content was considered and reported as up- and downregulation, respectively. ASt, Abnormal Savda type tumours; nASt, non-Abnormal Savda type tumours; NC, normal controls; n.d. no difference (fold change of less than 1.2 or more than 0.8); ASt/nASt, fold change of all differentially expressed proteins between ASt and nASt; ASt/NC or nASt/NC, fold change of the same proteins between ASt and NC or nASt and NC as those differentially expressed in ASt/nASt.
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us